Clinical trial · Observational
Basal Tumours in Bladder Cancer, Response to chemoTherapy
NCT04089748CI-TRIAL-00090658BoBCaTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Chemotherapy Effect | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| neoadjuvant chemotherapy with cisplatine | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients enrolled in VESPER study
- description
- Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort
- interventionNames
- Combination Product: neoadjuvant chemotherapy with cisplatine
- label
- Patients from St Louis cohort not enrolled in VESPER study
- description
- Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort
- interventionNames
- Combination Product: neoadjuvant chemotherapy with cisplatine
Primary outcomes (3)
- measure
- Identifying molecular subgroups of bladder cancer patients within VESPER and Saint-Louis cohort, who could benefit from neoadjuvant chemotherapy, taking into account the existence of different classification systems.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria of Patients enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and : * having signed an informed consent form for the participation to the collection or * dead/lost to follow-up without prior opposition expressed against research program, * genetic analysis will only be carried out for patients who have signed the genetic consent form. Inclusion Criteria of Patients from St Louis cohort not enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and : * having received an informed form for the participation to the collection and not having expressed opposition against research program within 1 month or * dead/lost to follow-up without prior opposition expressed against research program, Exclusion Criteria: -Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project. OR -Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.
References
Publications (0)
Data not yet available
No reference posted for this study.